• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氨基醇作为白三烯A4水解酶的高效、选择性及口服有效的抑制剂的发现。

Discovery of Amino Alcohols as Highly Potent, Selective, and Orally Efficacious Inhibitors of Leukotriene A4 Hydrolase.

作者信息

Thoma Gebhard, Markert Christian, Lueoend Rainer, Miltz Wolfgang, Spanka Carsten, Bollbuck Birgit, Wolf Romain M, Srinivas Honnappa, Penno Carlos A, Kiffe Michael, Gajewska Monika, Bednarczyk Dallas, Wieczorek Grazyna, Evans Amanda, Beerli Christian, Röhn Till A

机构信息

Global Discovery Chemistry, Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.

Chemical Biology & Therapeutics, Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.

出版信息

J Med Chem. 2023 Dec 14;66(23):16410-16425. doi: 10.1021/acs.jmedchem.3c01866. Epub 2023 Nov 28.

DOI:10.1021/acs.jmedchem.3c01866
PMID:38015154
Abstract

The discovery of chiral amino alcohols derived from our previously disclosed clinical LTA4H inhibitor is described. In a biochemical assay, their optical antipodes showed similar potencies, which could be rationalized by the cocrystal structures of these compounds bound to LTA4H. Despite comparable stabilities in liver microsomes, they showed distinct in vivo PK properties. Selective -phosphorylation of the ()-enantiomers in blood led to clearance values above the hepatic blood flow, whereas the ()-enantiomers were unaffected and exhibited satisfactory metabolic stabilities in vivo. Introduction of two pyrazole rings led to compound ()- with a more balanced distribution of polarity across the molecule, exhibiting high selectivity and excellent potency in vitro and in vivo. Furthermore, compound ()- showed favorable profiles in 16-week IND-enabling toxicology studies in dogs and rats. Based on allometric scaling and potency in whole blood, compound ()- has the potential for a low oral efficacious dose administered once daily.

摘要

本文描述了从我们之前公开的临床LTA4H抑制剂衍生而来的手性氨基醇的发现。在生化测定中,它们的旋光对映体显示出相似的效力,这可以通过这些化合物与LTA4H结合的共晶体结构来解释。尽管在肝微粒体中具有相当的稳定性,但它们在体内表现出不同的PK特性。血液中()-对映体的选择性磷酸化导致清除值高于肝血流量,而()-对映体不受影响,并在体内表现出令人满意的代谢稳定性。引入两个吡唑环导致化合物()-在整个分子中具有更平衡的极性分布,在体外和体内表现出高选择性和优异的效力。此外,化合物()-在犬和大鼠的16周IND支持毒理学研究中显示出良好的特征。基于异速生长标度和全血中的效力,化合物()-有可能每日给药一次的低口服有效剂量。

相似文献

1
Discovery of Amino Alcohols as Highly Potent, Selective, and Orally Efficacious Inhibitors of Leukotriene A4 Hydrolase.氨基醇作为白三烯A4水解酶的高效、选择性及口服有效的抑制剂的发现。
J Med Chem. 2023 Dec 14;66(23):16410-16425. doi: 10.1021/acs.jmedchem.3c01866. Epub 2023 Nov 28.
2
Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A Hydrolase.发现 LYS006,一种强效和高度选择性的白三烯 A 水解酶抑制剂。
J Med Chem. 2021 Feb 25;64(4):1889-1903. doi: 10.1021/acs.jmedchem.0c01955. Epub 2021 Feb 16.
3
Structure-Guided Elaboration of a Fragment-Like Hit into an Orally Efficacious Leukotriene A4 Hydrolase Inhibitor.基于结构的片段类似物优化:可口服的白三烯 A4 水解酶抑制剂。
J Med Chem. 2024 Mar 28;67(6):5093-5108. doi: 10.1021/acs.jmedchem.4c00290. Epub 2024 Mar 12.
4
Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.设计高效氨肽酶非选择性白三烯 A4 水解酶抑制剂的可行性和生理学相关性。
Sci Rep. 2017 Oct 19;7(1):13591. doi: 10.1038/s41598-017-13490-1.
5
A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.一种用于白三烯 A4 水解酶活性的体外和体内选择性测定的灵敏荧光底物。
Anal Biochem. 2013 Oct 15;441(2):152-61. doi: 10.1016/j.ab.2013.06.016. Epub 2013 Jul 11.
6
Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.基于混合受体结合/MM-GBSA逐残基能量的药效团建模:用于鉴定选择性LTA4H抑制剂作为潜在抗炎药物的增强方法。
Cell Biochem Biophys. 2017 Mar;75(1):35-48. doi: 10.1007/s12013-016-0772-3. Epub 2016 Dec 2.
7
LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial.LYS006 作为 LTA4H 抑制剂:一项随机、I 期临床试验中的临床药代动力学/药效学和安全性。
Clin Transl Sci. 2024 Feb;17(2):e13724. doi: 10.1111/cts.13724.
8
Synthesis, docking, cytotoxicity, and LTAH inhibitory activity of new gingerol derivatives as potential colorectal cancer therapy.新型姜辣素衍生物作为潜在的结直肠癌治疗药物的合成、对接、细胞毒性及脂氧合酶抑制活性
Bioorg Med Chem. 2017 Feb 1;25(3):1277-1285. doi: 10.1016/j.bmc.2016.12.048. Epub 2016 Dec 29.
9
Modulation of the 5-Lipoxygenase Pathway by Chalcogen-Containing Inhibitors of Leukotriene A Hydrolase.含硫/硒抑制剂对白细胞三烯 A 水解酶的 5-脂氧合酶途径的调节作用。
Int J Mol Sci. 2023 Apr 19;24(8):7539. doi: 10.3390/ijms24087539.
10
A remarkable activity of human leukotriene A4 hydrolase (LTA4H) toward unnatural amino acids.一种新型氨基酸对人白三烯 A4 水解酶(LTA4H)的显著活性。
Amino Acids. 2014 May;46(5):1313-20. doi: 10.1007/s00726-014-1694-2. Epub 2014 Feb 27.